Degradation of extracellular matrix (ECM) is an essential step in the process of angiogenesis, cellular invasion and tumor metastasis. The matrix metalloproteinases (MMPs), a family of structurally related zinc-dependent endoproteinases, are widely accepted to play a key role in these pro-2006 1 26 2006 1 31 , 135-710 50 02) 3410-3513․ 02) 3410-0630
cesses. 1 Under normal conditions, MMPs are tightly regulated at the level of gene transcription, activation of inactive zymogens, and inhibition by tissue inhibitors of metalloproteinases (TIMPs). 2 The major role of TIMPs is known to control MMPs activity by forming high-affinity complexes with the active forms of MMPs as well as controlling the activation process of MMPs. 3 Therefore, the MMPs/TIMPs balance is critical for the maintenance of the ECM. These properties identified with the MMPs/TIMPs have led to the development of synthetic MMP inhibitors for potential cancer drug therapy; however, the results of these potential treatments have so far been disappointing. 4 In addition to controlling MMPs, the TIMPs have been shown to have pluripotential effects on cell growth, apoptosis and differentiation. 5, 6 The effects of TIMPs on tumorigenesis are multifunctional and paradoxical. In contrast to their anti-MMP, anti-tumor effect, TIMP may also function in favor of tumor growth either in a MMP-independent or a MMP-dependent manner (Fig. 1 ). 6 TIMPs form a family of at least four members, TIMP-1, TIMP-1, -2 and -4 are secreted in soluble form, whereas TIMP-3 is insoluble and is bound to ECM proteins. 8 Despite their many basic similarities, they exhibit distinctive expres-sion patterns and phenotypic effects. 5 In addition, their phenotypic effects may vary from cell to tissue. For example, TIMP-2 has erythroid potentiating activity, 9 while it also acts to inhibit the growth of basic FGF-stimulated endothelial cells. 10 In addition, it has been shown that TIMP-2
can promote apoptosis in an in vivo colorectal cancer model, 11 while it has been also shown to protect B16 melanoma cells from apoptosis. 12 There have been many studies on the phenotypic effects of TIMPs. However, there are only a limited number of reports on the molecular mechanisms, receptors and signaling pathways of TIMPs to date. 13 Despite the well-known importance of TIMP-2 in the progression of carcinomas, few studies have examined TIMP-2 expression in ovarian cancer. Moreover, the findings of the few available reports on the expression patterns of TIMP-2 in ovarian cancer are not consistent. [14] [15] [16] [17] [18] [19] TIMP-2 expression in ovarian cancers seems to be variable and depends on the cell types studied and the detection methods employed.
The goals of this study were (1) Table 1 .
Formalin-fixed, paraffin-embedded 3 mm tissue sections Table 2 . Epithelial ovarian tumor cells showed intracytoplasmic and membranous staining for TIMP-2 (Fig. 2) . Stromal expression of TIMP-2 was also observed in some specimens, especially in the serous carcinomas ( Fig. 2H ). When the 4 groups (normal, benign, borderline and cancer) of specimens were compared with regard to the intensity of positive staining, the expression of TIMP-2 was significantly greater in serous carcinomas compared with the other groups (p=0.02, p 0.001, p=0.025, respectively) ( Fig. 3 ).
There was no correlation between the intensity of TIMP-2 immunostaining and international federation of gynecology and obstetrics (FIGO) stage or histologic grade in these tissues studied (p=0.788, p=0.441, respectively).
Our findings showed that TIMP-2 is up-regulated in serous 
Fig. 2. Representative examples of TIMP-2 staining in serous ovarian tumors. (A) TIMP-2 was detected in cytotrophoblast cells and in endothelial cells (positive control, placenta, ×200). (B) No staining was noted in normal ovarian epithelium or stroma (×200). (C) and (D), W eak staining of TIMP-2 in epithelial tumor cells of a serous cystadenoma. Smooth muscle cells of the vessel wall ( ) also showed staining of TIMP-2; the intensity was graded as weak (×40, ×200, respectively). (E) and (F) W eak staining of TIMP-2 in a borderline serous tumor (E, ×200) and intense staining in another borderline serous tumor (F, ×200). However, there was no staining in the stroma. (G) and (H), Serous carcinoma cells expressed intense staining of TIMP-2 (G, ×200) and cancer stromal cells showed weak staining (H, ×200).
ovarian carcinoma when compared with normal ovaries, benign serous cystadenomas and serous borderline tumors.
We could not find a significant correlation between TIMP-2 expression and FIGO stage or histologic grade in patients with serous carcinoma. Disease stage and histologic grade are well-known to have a prognostic value in ovarian carcinomas. However, the significant association between TIMP-2 expression and disease stage or histologic grade in ovarian carcinomas was not reported to date. Only a few studies have correlated TIMP-2 expression with prognosis in ovarian carcinomas. 18, 19, 29 Although Davidson, et al. 18, 19 suggested that TIMP-2 could be a valid marker for poor prognosis in advanced ovarian carcinoma, disease stage and histologic grade were not evaluated because of controlled study design.
To examine further TIMP-2 effect on prognosis or pathologic parameters, we think MMPs levels should also be evaluated in the well designed study series. stage III and nine stage IV) studied, these included many staining was localized mainly in tumor epithelium and not in the stroma, we suggest that host responses to increased TIMP-2 in serous ovarian tumorigenesis may be weak.
Alternatively, increased TIMP-2 expression may favor serous ovarian tumorigenesis by stimulating cell growth, by functioning to inhibit apoptosis, and by pro-MMP-2 activation. 6 In summary, we found the high level of expression of TIMP-2 in serous ovarian cancers using IHC. Additional studies are now needed to elucidate further the role of TIMP-2 in the biology of ovarian serous tumors. 
